Stock Movers: Oracle's Cloud Sales Miss, Gemini's Prediction Market Approval, Eli Lilly's Obesity Drug Success

Oracle's Cloud Sales Disappointment

• 📉 Shares of Oracle (ORCL) saw a significant drop due to cloud sales falling short of analysts' estimates, despite a 34% increase in fiscal second-quarter cloud sales.
• 💡 Oracle is investing heavily in a massive data center build-out to power AI work for clients like OpenAI, ByteDance, and Meta.
• ⚠️ Concerns were raised by Wall Street regarding the costs and time required for building AI infrastructure at such a large scale.
• 📈 Oracle increased its 2026 cap spending outlook by $15 billion to $50 billion, with a significant portion allocated to revenue-generating equipment.

Gemini Space Station's Prediction Market Entry

• 🚀 Gemini Space Station Inc. (GEMI) experienced a rally after its application for a derivatives exchange was approved by the Commodity Futures Trading Commission.
• 🎯 This approval allows Gemini, co-founded by the Winklevoss twins, to enter the prediction markets field.
• 📊 The company plans to offer trading on event contracts covering economic, financial, political, and sports forecasts to US customers.

Eli Lilly's Promising Obesity Shot

• ✨ Eli Lilly & Co. (LLY) saw its shares jump following positive results from its next-generation obesity drug, retatrutide.
• 💊 In a late-stage study, patients on the highest dose lost over 23% of their body weight in 68 weeks, potentially making it the most potent weight loss medicine available.
• 🩹 The study also measured a more than 62% reduction in knee pain associated with osteoarthritis, a condition linked to obesity.
• ⚠️ Some patients in the study had to drop out due to experiencing excessive weight loss.